US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line ...

Retrieved on: 2024-04-07 05:49:42

Tags for this article:

Orphan drugs

Cancer immunotherapy

Bispecific monoclonal antibody

Biopharmaceutical

Treatment of lung cancer

PD-1 and PD-L1 inhibitors

Biocytogen Pharmaceuticals (Beijing) Co. Ltd.

TRACON Pharmaceuticals Inc

biocytogen pharmaceuticals (beijing)

Click the tags to see associated articles and topics

US FDA Approval of IND for CTLA-4 Antibody YH001 for the Treatment of Front-line .... View article details on HISWAI: https://www.theglobeandmail.com/investing/markets/stocks/TCON/pressreleases/9926294/us-fda-approval-of-ind-for-ctla-4-antibody-yh001-for-the-treatment-of-front-line-sarcoma-patients-in-combination-with-envafolimab/

Summary

Biocytogen and TRACON Pharmaceuticals announce FDA approval for a Phase 1/2 clinical study of a novel biopharma therapy, YH001, targeting CTLA-4 in combination with envafolimab and doxorubicin for treating sarcoma. The study focuses on rare and common sarcoma subtypes, highlighting advancements in cancer immunotherapy and biotechnology.

Article found on: www.theglobeandmail.com

View Original Article